Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,545 | 13,824 | 12,227 | 36,279 | 7,850 |
| Marketable Securities | 115,594 | 120,264 | 102,691 | 80,165 | N/A |
| Receivables | 78 | 76 | 82 | 73 | 72 |
| TOTAL | $125,466 | $134,405 | $115,245 | $116,940 | $8,298 |
| Non-Current Assets | |||||
| PPE Net | 2 | 3 | 4 | 5 | 6 |
| Other Non-Current Assets | 132 | 152 | 172 | 191 | 210 |
| TOTAL | $134 | $155 | $176 | $196 | $216 |
| Total Assets | $125,599 | $134,559 | $115,421 | $117,136 | $8,514 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 729 | 965 | 1,103 | 523 | 1,267 |
| Accrued Expenses | 2,661 | 1,361 | 1,158 | 825 | 1,014 |
| TOTAL | $3,390 | $2,326 | $2,261 | $1,458 | $2,537 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $3,390 | $2,326 | $2,261 | $1,458 | $2,537 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 16,242 | 16,024 | 15,198 | N/A | 10,275 |
| Common Shares | 16 | 16 | 15 | 15 | 10 |
| Retained earnings | -158,553 | -141,651 | -130,532 | -119,859 | -115,332 |
| TOTAL | $122,210 | $132,233 | $113,160 | $115,678 | $5,977 |
| Total Liabilities And Equity | $125,600 | $134,560 | $115,421 | $117,136 | $8,514 |